search
Back to results

Early and Systematic Screening in Chronic Neuropathy (TTR-FAP)

Primary Purpose

Amyloid Neuropathies, Familial

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Systematic screening of TTR mutations
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Amyloid Neuropathies, Familial focused on measuring proportion, TTR-FAP, study, neuropathy

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients of both sexes presenting chronically (> 3 months):

    • neuropathy confirmed by an electroneuromyography
    • without obvious etiology (diabetes, alcohol consumption, renal insufficiency, neurotoxic substances intake, family history of diagnosed hereditary neuropathy)
    • without anomaly of the following biological examinations: fasting blood glucose, blood count, gamma-glutamyl transferases, average cell volume, transaminases, serum creatinine clearance, C-reactive protein, TSH
  • Aged 18 to 90 years Patients giving their free and informed consent to participate, after research information

Exclusion Criteria:

  • People placed under the protection of justice.
  • Patients who are not affiliated or who are not beneficiaries of a social security scheme
  • Patients with chronic neuropathy related to a known etiology

Sites / Locations

  • Reference center for neuromuscular diseases

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

patients with chronic neuropathy of unknown aetiology

Arm Description

For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.

Outcomes

Primary Outcome Measures

Diagnosis of TTR-FAP
Proportion of TTR-FAP in the 130 patients with chronic neuropathy of unknown aetiology

Secondary Outcome Measures

Age of patient at diagnosis
History of dysautonomias
History of dysautonomias at the interview
Signs of dysautonomias
signs of dysautonomias at the interview
Weight of patient
weight
Height of patient
height
Motor deficit of the lower limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
The Motor deficit of the lower limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the NIS scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.
Motor deficit of the upper limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
The Motor deficit of the upper limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.
Sensory deficit evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
The Sensory deficit will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The sensory sub score is scored on 20 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.
Presence / Absence of reflexes osteo-tendinous evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
The Presence/Absence of reflexes osteo-tendinous will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 88 points. The reflexes sub score is scored on 8 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.
Presence of orthostatic hypotension
Blood pressure measurement by the nurse
Dysautonomia score
Score at the clinical scale assessing autonomic dysfunction according to 5 modalities: orthostatic hypotension, high digestive motor disorders, low digestive motor disorders, vesicosphincteric disorders, erectile dysfunction
Rasch-built Overall Disability Scale (RODS) score
Score at the RODS, a functional scale that captures daily activity and social participation limitations in patients affected by polyneuropathy (self-questionnaire)
Overall Neuropathy Limitations Scale (ONLS) score
The ONLS is a validated neuropathy functional scale evaluating the performance of upper and lower cells. The upper limbs sub score is scored on 5 points and the lower limbs sub score is scored on 7 points. The scale thus ranges from 0 (no disability) to 12 points (disability maximum)
Electroneuromyography findings (ENMG): axonal, demyelinating or mixed neuropathy).

Full Information

First Posted
October 12, 2018
Last Updated
October 5, 2023
Sponsor
University Hospital, Bordeaux
Collaborators
University of Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT03720275
Brief Title
Early and Systematic Screening in Chronic Neuropathy
Acronym
TTR-FAP
Official Title
Evaluation of a New Diagnostic Approach to Familial Amyloid Neuropathy by Mutation of the TTR Gene in a Population of Idiopathic Chronic Neuropathies
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
November 27, 2018 (Actual)
Primary Completion Date
May 27, 2020 (Actual)
Study Completion Date
December 23, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
University of Bordeaux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
TTR-FAP is a rare disabling inherited disorder that predominantly affects the peripheral nervous system and the heart. Due to an important phenotypic and genetic heterogeneity, the diagnosis is often delayed, preventing therefore early onset treatment. Our project is to evaluate the prevalence of TTR-FAP in a series of 130 patients with from chronic neuropathy of undetermined aetiology through a systematic screening of TTR mutations.
Detailed Description
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an autosomal dominant disorder, highly disabling and life-threatening, resulting of transthyretin (TTR) gene mutation. Clinically, TTR FAP is characterized by progressive sensorimotor and dysautonomic neuropathy, usually fatal within a few years. The disease prevalence is highly variable, with a large genotypic and phenotypic heterogeneity. Early and accurate diagnosis remains essential to propose early treatment. New pharmacotherapies have been developed, such as Tafamidis®, and many patients can avoid liver transplant formerly considered as the only therapeutic option. The prevalence of TTR-FAP disease has been previously estimated in series of patients with severe and progressive neuropathy, frequently leading to a delayed diagnosis. TTR-FAP is also easily suspected when neuropathy is associated with cardiac symptoms or dysautonomia. Currently, genetic testing of TTR-FAP is targeted and is only prescribed to patients in whom the first-line assessment recommended by the High Authority for Health (HAS) did not identify a cause, and on the basis of a worsening of symptoms. An early diagnosis in those cases would allow earlier treatment and monitoring. No data are available about the prevalence of TTR-FAP in populations of patients with from chronic neuropathy of unknown aetiology, through a systematic screening of TTR mutations. The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene. The patients with a diagnosis of TTR-FAP confirmed during this study will be seen for an additional visit in the Investigating Centre and proposed suitable follow up, treatment and care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyloid Neuropathies, Familial
Keywords
proportion, TTR-FAP, study, neuropathy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
130 (Actual)

8. Arms, Groups, and Interventions

Arm Title
patients with chronic neuropathy of unknown aetiology
Arm Type
Experimental
Arm Description
For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
Intervention Type
Genetic
Intervention Name(s)
Systematic screening of TTR mutations
Intervention Description
The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
Primary Outcome Measure Information:
Title
Diagnosis of TTR-FAP
Description
Proportion of TTR-FAP in the 130 patients with chronic neuropathy of unknown aetiology
Time Frame
Genetic analyzes will be performed every three months from the first inclusion
Secondary Outcome Measure Information:
Title
Age of patient at diagnosis
Time Frame
at the inclusion visit
Title
History of dysautonomias
Description
History of dysautonomias at the interview
Time Frame
at the inclusion visit
Title
Signs of dysautonomias
Description
signs of dysautonomias at the interview
Time Frame
at the inclusion visit
Title
Weight of patient
Description
weight
Time Frame
at the inclusion visit
Title
Height of patient
Description
height
Time Frame
at the inclusion visit
Title
Motor deficit of the lower limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
Description
The Motor deficit of the lower limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the NIS scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.
Time Frame
at the inclusion visit
Title
Motor deficit of the upper limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
Description
The Motor deficit of the upper limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.
Time Frame
at the inclusion visit
Title
Sensory deficit evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
Description
The Sensory deficit will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The sensory sub score is scored on 20 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.
Time Frame
at the inclusion visit
Title
Presence / Absence of reflexes osteo-tendinous evaluated by a subscore of the Neuropathy Impairment Scale (NIS)
Description
The Presence/Absence of reflexes osteo-tendinous will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 88 points. The reflexes sub score is scored on 8 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.
Time Frame
at the inclusion visit
Title
Presence of orthostatic hypotension
Description
Blood pressure measurement by the nurse
Time Frame
at the inclusion visit
Title
Dysautonomia score
Description
Score at the clinical scale assessing autonomic dysfunction according to 5 modalities: orthostatic hypotension, high digestive motor disorders, low digestive motor disorders, vesicosphincteric disorders, erectile dysfunction
Time Frame
at the inclusion visit
Title
Rasch-built Overall Disability Scale (RODS) score
Description
Score at the RODS, a functional scale that captures daily activity and social participation limitations in patients affected by polyneuropathy (self-questionnaire)
Time Frame
at the inclusion visit
Title
Overall Neuropathy Limitations Scale (ONLS) score
Description
The ONLS is a validated neuropathy functional scale evaluating the performance of upper and lower cells. The upper limbs sub score is scored on 5 points and the lower limbs sub score is scored on 7 points. The scale thus ranges from 0 (no disability) to 12 points (disability maximum)
Time Frame
at the inclusion visit
Title
Electroneuromyography findings (ENMG): axonal, demyelinating or mixed neuropathy).
Time Frame
at the inclusion visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients of both sexes presenting chronically (> 3 months): neuropathy confirmed by an electroneuromyography without obvious etiology (diabetes, alcohol consumption, renal insufficiency, neurotoxic substances intake, family history of diagnosed hereditary neuropathy) without anomaly of the following biological examinations: fasting blood glucose, blood count, gamma-glutamyl transferases, average cell volume, transaminases, serum creatinine clearance, C-reactive protein, TSH Aged 18 to 90 years Patients giving their free and informed consent to participate, after research information Exclusion Criteria: People placed under the protection of justice. Patients who are not affiliated or who are not beneficiaries of a social security scheme Patients with chronic neuropathy related to a known etiology
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guilhem Solé, MD
Organizational Affiliation
University Hospital Bordeaux, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Reference center for neuromuscular diseases
City
Bordeaux
ZIP/Postal Code
33076
Country
France

12. IPD Sharing Statement

Learn more about this trial

Early and Systematic Screening in Chronic Neuropathy

We'll reach out to this number within 24 hrs